Standard BioTools shares surge 20.22% intraday after exceeding 2025 revenue guidance and announcing SomaLogic sale to Illumina.
ByAinvest
Thursday, Jan 8, 2026 1:05 pm ET1min read
LAB--
Standard BioTools (NASDAQ: LAB) surged 20.22% intraday after announcing preliminary 2025 revenue of $185 million for combined operations and $85 million from continuing operations, exceeding guidance. The company highlighted exceeding expectations amid cost-optimization efforts and a path toward positive adjusted EBITDA. CEO Michael Egholm emphasized strategic improvements, including a streamlined operating model and $550 million in anticipated cash from the pending SomaLogic sale to Illumina, scheduled for H1 2026. These developments, coupled with strong full-year execution, underscored the stock’s sharp intraday rally as investors reacted favorably to the revenue outperformance and enhanced strategic flexibility.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet